HeyJaredKeith Speights
- Indexed articles, last 90 days
- 59
- Latest publication
- Sep 20, 2026
- Outlet visibility, for yahoo.com
- Top 1K sites
- Earliest in this view
- Jul 5, 2026
Latest articles
2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right. (opens the original)
Read excerpt
Argenx (NASDAQ: ARGX) has been a solid winner for investors over the last 12 months, with its shares rising by roughly 30%. Wall Street thinks that the biotech stock can go even higher. The consensus one-year price target for Argenx reflects a potential upside of around 20%. Two analysts, though, are even more bullish. Wells Fargo's (NYSE: WFC) Derek Archila and UBS' (NYSE: UBS) Xian Deng predict that Argenx's share price can soar more than 40% over the next 12 months. Here's why they're probabl
The Fed Could Be About to Raise Rates for the First Time Since 2023. Here's What History Says Happens to Stocks Next. (opens the original)
Read excerpt
Over three years. That's how long it's been since the Federal Reserve last raised the federal funds rate, the interest rate that commercial banks charge each other for overnight borrowing. This stretch seems likely to end when the Federal Open Market Committee (FOMC) announces the outcome of its latest meeting on Wednesday, Sept. 16, 2026. Going into the FOMC's announcement, CME Group's (NASDAQ:CME) FedWatch estimated the probability of a rate hike at a whopping 92.7%. FedWatch's odds of rate in
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture (opens the original)
Read excerpt
There's no way to spin Alnylam Pharmaceuticals' (NASDAQ: ALNY) stock performance in 2026 in a positive light. It's been downright ugly. Alnylam's share price plunged more than 50% year-to-date earlier this summer and remains around 40% below its peak. You might think that most Wall Street analysts would have thrown in the towel on Alnylam. However, that isn't the case at all. Instead, analysts remain overwhelmingly bullish about the biotech stock. Missed Nvidia in 2009? This Rare Signal Is Flash
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. (opens the original)
Read excerpt
Novartis (NYSE: NVS) just reported its third clinical failure in only seven days. One of the company's pipeline setbacks triggered a ripple impact throughout one of the most hotly anticipated drug races in the biopharmaceutical industry. Analysts are still trying to fully assess how much Novartis shook up the cardiovascular medicine space. But the world's largest healthcare company by market cap has found itself caught in the crossfire -- Eli Lilly (NYSE: LLY). Missed Nvidia in 2009? This Rare S
Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock (opens the original)
Read excerpt
The adage that "birds of a feather flock together" doesn't always apply to billionaire investors. Most of these super-successful individuals have their own unique strategies that are highly differentiated from other approaches. However, that doesn't mean high-profile investors don't sometimes see eye-to-eye on a given stock. For example, Stanley Druckenmiller and Ken Griffin both loaded up on Eli Lilly (NYSE: LLY) stock in the second quarter of 2026. Here's why these billionaires are on the same
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1K sites
For yahoo.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.